View in EDS

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.

Saved in:

Bibliographic Details
Title:	ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.
Authors:	Hayashi H; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan hayashi.hiroki24@chugai-pharm.co.jp., Tatsumi K; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Katada H; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Matsuda Y; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Tsunenari T; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Honda M; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Nemoto T; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Shimizu S; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Miura-Okuda M; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Ikuta Y; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Ito A; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Ogami C; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Chuo-ku, Tokyo, Japan., Kato C; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Kamimura M; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Kibayashi T; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Kubo C; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Komatsu S; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Komori Y; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Shinozuka J; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Susumu H; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Tanno H; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Tomii Y; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Nakagawa K; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Nagano H; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Nanami M; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Nishito Y; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Fujisawa N; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Matsushita T; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan., Michisaka S; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Yamazaki M; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Yoshimoto M; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Wakatsuki H; Chugai Pharmaceutical Co., Ltd., Translational Research Div, Chuo-ku, Tokyo, Japan., Wakabayashi T; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Wada NA; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Ueda O; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Konishi H; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Kashima K; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Tanaka H; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Endo M; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Kitazawa T; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Sakaguchi S; Experimental Immunology, Immunology Frontier Research Center; Osaka University, Suita, Osaka, Japan., Kamata-Sakurai M; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan., Igawa T; Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan.
Source:	Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jan 09; Vol. 14 (1). Date of Electronic Publication: 2026 Jan 09.
Publication Type:	Journal Article
Journal Info:	Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2051-1426
DOI:	10.1136/jitc-2025-013397